Effects of proANP 31–67 in a preclinical model of uninephrectomy and cardiac ischemia/reperfusion injury: cardiac remodeling and tissue biochemical profiling
American Journal of Physiology-Cell Physiology · 01.05.2026 · 330 (5) · C1246-C1259
DOI: 10.1152/ajpcell.00339.2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.05.2026. Verfasst von Gustavo Jose Justo Silva und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Ventricular Remodeling, Atrial Natriuretic Factor, Nephrectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Nasjonalforeningen for Folkehelsen (Norwegian Health Association), The Research Council of Norway, EC | NextGenerationEU (NGEU).
Abstract (Originalsprache)
In a model of reduced nephron mass combined with cardiac ischemia/reperfusion injury, proANP 31–67 prevented adverse cardiac remodeling independent of blood pressure. Vibrational spectroscopy identified coordinated biochemical alterations in cardiac and renal tissues not detected by conventional assays, providing molecular-level insight into cardiorenal remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
- K.G. Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway.
- Department of Molecular Medicine, Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway.
- Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia, Italy.
- Department of Physiology, University of Auckland, Auckland, New Zealand.
- Department of Cardiology, Oslo Center for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway.
ORCID-Profile: Gustavo Jose Justo Silva, Sara Stefani, Reza Parvan, Michael Frisk, Xin Shen, Martina Alunni Cardinali, Mari E Strand, Karoline Bjarnesdatter Rypdal, Mathis Korseberg Stokke, Håvard Attramadal, Ida G Lunde, Kåre-Olav Stensløkken, William E Louch, Paola Sassi, Alessandro Cataliotti
Förderung
- Nasjonalforeningen for Folkehelsen (Norwegian Health Association)
- The Research Council of Norway
- EC | NextGenerationEU (NGEU)
- HOD | Helse Sør-Øst RHF (sorost)
Zitieren
APA
Silva, G. J. J., Stefani, S., Parvan, R., Frisk, M., Shen, X., Alunni Cardinali, M., Strand, M. E., Rypdal, K. B., Stokke, M. K., Attramadal, H., Lunde, I. G., Aronsen, J. M., Stensløkken, K. O., Louch, W. E., Sassi, P., & Cataliotti, A. (2026). Effects of proANP 31–67 in a preclinical model of uninephrectomy and cardiac ischemia/reperfusion injury: cardiac remodeling and tissue biochemical profiling. American Journal of Physiology-Cell Physiology, 330(5), C1246-C1259. https://doi.org/10.1152/ajpcell.00339.2025
Vancouver
Silva GJJ, Stefani S, Parvan R, Frisk M, Shen X, Alunni Cardinali M, et al. Effects of proANP 31–67 in a preclinical model of uninephrectomy and cardiac ischemia/reperfusion injury: cardiac remodeling and tissue biochemical profiling. American Journal of Physiology-Cell Physiology. 2026;330(5):C1246-C1259. doi:10.1152/ajpcell.00339.2025
BibTeX
@article{Silva2026,
author = {Silva, Gustavo Jose Justo and Stefani, Sara and Parvan, Reza and Frisk, Michael and Shen, Xin and Alunni Cardinali, Martina and Strand, Mari E and Rypdal, Karoline Bjarnesdatter and Stokke, Mathis Korseberg and Attramadal, Håvard and Lunde, Ida G and Aronsen, Jan Magnus and Stensløkken, Kåre-Olav and Louch, William E and Sassi, Paola and Cataliotti, Alessandro},
title = {Effects of proANP 31–67 in a preclinical model of uninephrectomy and cardiac ischemia/reperfusion injury: cardiac remodeling and tissue biochemical profiling},
journal = {American Journal of Physiology-Cell Physiology},
year = {2026},
volume = {330},
number = {5},
pages = {C1246--C1259},
doi = {10.1152/ajpcell.00339.2025}
}
EUVIMED